SDS‐CRISPR for Single‐Nucleotide Variant Detection

alleles with attomole sensitivity and 0.01% variant frequency. To facilitate intraoperative use, we combine SDS-CRISPR with a lateral-flow strip and an artificial intelligence-assisted smartphone reader, enabling on-site detection within 20 min. Clinical validation with 43 glioma tissue samples shows high concordance with immunohistochemistry, while plasma cfDNA testing demonstrates mutation fractions consistent with next-generation sequencing. Beyond glioma, SDS-CRISPR generalizes across molecular targets, discriminating microRNA isoforms and identifying HIV-1 drug-resistance mutations. Together, these results establish SDS-CRISPR as a universal, mechanistically informed, and clinically actionable framework for precision molecular diagnostics.